News Agency
The Times

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma

  • Written by PR Newswire
PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma
  • Based on promising early clinical results from PeproMene Bio's PMB-102 Phase 1 study, they will receive $6M USD upfront plus an additional $5M USD in conditional tranched investments from the Institute for Follicular Lymphoma Innovation.
  • Patients with relapsed/refractory follicular lymphoma will be included in the expansion phase of PeproMene...

Read more: PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment...

How Can Businesses Reduce the Risk of Commercial Litigation?

Commercial disputes often begin with a misunderstanding, an unclear contract or a delayed response to a growing problem. Seeking early advice from Litigation Lawyers Sydney with PCL lawyers can help businesses trust and identify legal risks, clarify obligations and create a strategy... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion